Incannex Healthcare Inc. (NASDAQ: IXHL) completed a $75 million capital raise on March 18 2026, leaving the company with no debt and a cash balance that supports a 12‑month operational runway. The financing was led by healthcare‑focused institutional investors and is the largest round the company has raised since its March 12 2026 $10 million direct offering.
The new capital will be directed primarily to the DReAMzz Phase 2 crossover dose‑optimization study for the company’s lead candidate IHL‑42X, a fixed‑dose combination for obstructive sleep apnea. Management indicated that the funds will also preserve a substantial portion of the balance sheet for an optimized Phase 3 program, while additional resources will support the development of PSX‑001, an oral synthetic psilocybin therapy for generalized anxiety disorder.
"Following the completion of this financing, Incannex is in a strong financial position — approximately $75 million in cash, no debt, and well‑funded through our DReAMzz study and into an optimized Phase 3 program. This disciplined capital strategy allows us to advance IHL‑42X from a position of financial strength while maintaining a robust balance sheet as we progress toward late‑stage development and potential registration," said President and CEO Joel Latham.
Prior to this round, Incannex had reported over $70 million in cash in January 2026 and had raised $10 million in March 12 2026, bringing the total cash position to roughly $75 million. The company also regained Nasdaq minimum bid price compliance on March 17 2026, removing a technical listing overhang. Despite the strong balance sheet, the company’s market capitalization of about $46 million creates a negative enterprise value, a disconnect that management believes is unsustainable and will be corrected through continued execution.
The financing strengthens Incannex’s ability to advance its flagship pipeline without immediate funding pressure, while the valuation gap highlights potential upside for investors who view the company’s clinical progress and institutional backing as undervalued. The move also signals confidence from healthcare‑focused investors in the long‑term value of IHL‑42X and the broader pipeline, positioning the company for the next milestones in its development roadmap.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.